BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Mol Ther 2015;23:1772-82. [PMID: 26278330 DOI: 10.1038/mt.2015.147] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Poilil Surendran S, George Thomas R, Moon MJ, Jeong YY. Nanoparticles for the treatment of liver fibrosis. Int J Nanomedicine. 2017;12:6997-7006. [PMID: 29033567 DOI: 10.2147/ijn.s145951] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 7.4] [Reference Citation Analysis]
2 Hameed S, Bhattarai P, Dai Z. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment. Sci China Life Sci 2018;61:380-91. [PMID: 29607461 DOI: 10.1007/s11427-017-9256-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
3 Kudo M. Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer 2021;10:85-93. [PMID: 33977086 DOI: 10.1159/000514312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Peng WT, Sun WY, Li XR, Sun JC, Du JJ, Wei W. Emerging Roles of G Protein-Coupled Receptors in Hepatocellular Carcinoma. Int J Mol Sci. 2018;19. [PMID: 29734668 DOI: 10.3390/ijms19051366] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
5 Zhou Y, Yu F, Zhang F, Chen G, Wang K, Sun M, Li J, Oupický D. Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition To Treat Metastatic Breast Cancer. Biomacromolecules 2018;19:392-401. [PMID: 29350899 DOI: 10.1021/acs.biomac.7b01487] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
6 Bartneck M. Immunomodulatory Nanomedicine. Macromol Biosci 2017;17:1700021. [DOI: 10.1002/mabi.201700021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
7 Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:630-47. [PMID: 33976393 DOI: 10.1038/s41575-021-00444-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
8 Hu M, Huang L. Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver. Adv Funct Mater 2018. [DOI: 10.1002/adfm.201805760] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
9 De Francesco EM, Sotgia F, Clarke RB, Lisanti MP, Maggiolini M. G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts. Int J Mol Sci 2017;18:E2713. [PMID: 29240722 DOI: 10.3390/ijms18122713] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
10 Jia Y, Omri A, Krishnan L, McCluskie MJ. Potential applications of nanoparticles in cancer immunotherapy. Hum Vaccin Immunother 2017;13:63-74. [PMID: 27870598 DOI: 10.1080/21645515.2016.1245251] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
11 Ball RL, Hajj KA, Vizelman J, Bajaj P, Whitehead KA. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA. Nano Lett 2018;18:3814-22. [PMID: 29694050 DOI: 10.1021/acs.nanolett.8b01101] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 17.0] [Reference Citation Analysis]
12 Zhang F, Gong S, Wu J, Li H, Oupicky D, Sun M. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy. Biomacromolecules 2017;18:1793-802. [DOI: 10.1021/acs.biomac.7b00208] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
13 Wang K, Kievit FM, Zhang M. Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies. Pharmacological Research 2016;114:56-66. [DOI: 10.1016/j.phrs.2016.10.016] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 10.3] [Reference Citation Analysis]
14 Xie Y, Wang Y, Li J, Hang Y, Oupický D. Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019;11:e1528. [PMID: 29700990 DOI: 10.1002/wnan.1528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Zhang H, Sun L, Hu X. Macrophages M1-Related Prognostic Signature in Hepatocellular Carcinoma. J Oncol 2021;2021:6347592. [PMID: 34745260 DOI: 10.1155/2021/6347592] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, Tang W. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18:130. [PMID: 31464625 DOI: 10.1186/s12943-019-1047-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
17 Zhang C, Hang Y, Tang W, Sil D, Jensen-smith HC, Bennett RG, Mcvicker BL, Oupický D. Dually Active Polycation/miRNA Nanoparticles for the Treatment of Fibrosis in Alcohol-Associated Liver Disease. Pharmaceutics 2022;14:669. [DOI: 10.3390/pharmaceutics14030669] [Reference Citation Analysis]
18 Parvani JG, Jackson MW. Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles. Endocr Relat Cancer 2017;24:R81-97. [PMID: 28148541 DOI: 10.1530/ERC-16-0482] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
19 Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67:603-618. [PMID: 28438689 DOI: 10.1016/j.jhep.2017.04.009] [Cited by in Crossref: 178] [Cited by in F6Publishing: 186] [Article Influence: 35.6] [Reference Citation Analysis]
20 Mousavi A. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. Immunol Lett 2020;217:91-115. [PMID: 31747563 DOI: 10.1016/j.imlet.2019.11.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
21 Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. J Exp Clin Cancer Res 2019;38:232. [PMID: 31151472 DOI: 10.1186/s13046-019-1216-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
22 Majumder P, Bhunia S, Chaudhuri A. A lipid-based cell penetrating nano-assembly for RNAi-mediated anti-angiogenic cancer therapy. Chem Commun 2018;54:1489-92. [DOI: 10.1039/c7cc08517f] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
23 Soond SM, Zamyatnin AA Jr. Targeting G protein-coupled receptors in cancer therapy. Adv Cancer Res 2020;145:49-97. [PMID: 32089165 DOI: 10.1016/bs.acr.2019.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Scarabel L, Perrone F, Garziera M, Farra R, Grassi M, Musiani F, Russo Spena C, Salis B, De Stefano L, Toffoli G, Rizzolio F, Tonon F, Abrami M, Chiarappa G, Pozzato G, Forte G, Grassi G, Dapas B. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. Expert Opinion on Drug Delivery 2017;14:797-810. [DOI: 10.1080/17425247.2017.1292247] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
25 Wang S, Gao S, Li Y, Qian X, Luan J, Lv X. Emerging Importance of Chemokine Receptor CXCR4 and Its Ligand in Liver Disease. Front Cell Dev Biol 2021;9:716842. [PMID: 34386499 DOI: 10.3389/fcell.2021.716842] [Reference Citation Analysis]
26 Mroweh M, Decaens T, Marche PN, Macek Jilkova Z, Clément F. Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5250. [PMID: 32722054 DOI: 10.3390/ijms21155250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Roveri M, Bernasconi M, Leroux J, Luciani P. Peptides for tumor-specific drug targeting: state of the art and beyond. J Mater Chem B 2017;5:4348-64. [DOI: 10.1039/c7tb00318h] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
28 Siegler EL, Kim YJ, Wang P. Nanomedicine targeting the tumor microenvironment: Therapeutic strategies to inhibit angiogenesis, remodel matrix, and modulate immune responses. Journal of Cellular Immunotherapy 2016;2:69-78. [DOI: 10.1016/j.jocit.2016.08.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
29 Zheng J, Gao P. Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr Cancer Ther 2019;18:1534735419862352. [PMID: 31282197 DOI: 10.1177/1534735419862352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
30 Bartneck M, Wang J. Therapeutic Targeting of Neutrophil Granulocytes in Inflammatory Liver Disease. Front Immunol 2019;10:2257. [PMID: 31616430 DOI: 10.3389/fimmu.2019.02257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
31 Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
32 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
33 Yang Z, Duan J, Wang J, Liu Q, Shang R, Yang X, Lu P, Xia C, Wang L, Dou K. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy. Int J Nanomedicine 2018;13:1851-65. [PMID: 29618926 DOI: 10.2147/IJN.S155537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
34 Chen H, Chan S, Liu X, Wei A, Jian R, Huang K, Lang Y, Shih J, Liao C, Luan C, Kao Y, Chiang S, Hsiao P, Jou Y, Chen Y, Chen R. Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression. J Hematol Oncol 2022;15. [DOI: 10.1186/s13045-022-01306-3] [Reference Citation Analysis]
35 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307-319. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 69.0] [Reference Citation Analysis]
36 Samie HAA, Saeed M, Faisal SM, Kausar MA, Kamal MA. Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma. CDM 2019;20:283-91. [DOI: 10.2174/1389200220666190308134351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Janssens R, Struyf S, Proost P. Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Rev 2018;44:51-68. [PMID: 30396776 DOI: 10.1016/j.cytogfr.2018.10.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
38 Peng W, Cheng S, Bao Z, Wang Y, Zhou W, Wang J, Yang Q, Chen C, Wang W. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. Biomedicine & Pharmacotherapy 2021;137:111342. [DOI: 10.1016/j.biopha.2021.111342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 van Tienderen GS, Groot Koerkamp B, IJzermans JNM, van der Laan LJW, Verstegen MMA. Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment. Cancers (Basel). 2019;11. [PMID: 31683901 DOI: 10.3390/cancers11111706] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
40 Mullick Chowdhury S, Wang TY, Bachawal S, Devulapally R, Choe JW, Abou Elkacem L, Yakub BK, Wang DS, Tian L, Paulmurugan R, Willmann JK. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Control Release 2016;238:272-80. [PMID: 27503707 DOI: 10.1016/j.jconrel.2016.08.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
41 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 31.0] [Reference Citation Analysis]
42 Liu CH, Chan KM, Chiang T, Liu JY, Chern GG, Hsu FF, Wu YH, Liu YC, Chen Y. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis. Mol Pharm 2016;13:2253-62. [PMID: 27224003 DOI: 10.1021/acs.molpharmaceut.5b00913] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
43 Huang Y, Wang T, Yang J, Wu X, Fan W, Chen J. Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review. Int J Nanomedicine 2022;17:2335-52. [PMID: 35619893 DOI: 10.2147/IJN.S363456] [Reference Citation Analysis]